Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)
Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)
Background:

 Myotonic dystrophy is a long-term genetic disorder that affects muscle function. Symptoms
 include gradually worsening muscle loss and weakness. Muscles often contract and cannot
 relax. Researchers want to find out how various tests for DM1 or DM2 change over 2 years, to
 help them develop better tests for people with these diseases. Data and samples from this
 study will be shared with the Myotonic Dystrophy Clinical Research Network (DMCRN)
 investigators participating in the ongoing Establishing Biomarkers and Clinical Endpoints in
 Myotonic Dystrophy Type 1 (ENDDM1) study

 Objective:

 To find better ways to assess how myotonic dystrophy type 1 or type 2 affects people.

 Eligibility:

 People ages 11 70 with DM1 or DM2

 Design:

 Participants will have 3 study visits over 2 years. Participants may be admitted to the
 clinic. Each visit may last up to a week and will include:

 Medical history and physical exam

 Blood, heart, and pregnancy tests

 Questions about their disease

 Breathing and muscle tests, including tests of movement, grip, and hand opening

 Speech and swallowing exam

 Magnetic resonance imaging (MRI). Participants will lie on a table that slides into a
 cylinder.

 A magnetic field and radio waves will take pictures of the body. They may do a task during
 the scan. They may have a dye injected.

 Pictures of chemicals in the brain or muscle taken in an MRI scanner

 Thinking and memory tests

 Sleep studies. Electrodes placed on the scalp will record the electrical activity of the
 brain.

 Other devices on the body will measure heartbeat, breathing, movement, and oxygen.

 Tests of electrical activity of muscles. Participants move their arms and legs with disks
 stuck on their skin.

 Visits may also include:

 Exam by a physician expert in stomach and bowel disorders

 A piece of muscle and/or spinal fluid removed by needle

 Sponsoring Institute: National Institute of Neurological Disorders and Stroke

 ...
Objective: Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are the most common inherited
 skeletal myopathies in adults. RNA toxicity is the core disease mechanism, good molecular
 targets have been identified and there has been rapid progress in developing targeted
 therapies. However, incomplete characterization and limited biologic understanding of
 phenotypic heterogeneity, and lack of reliable clinical endpoints and biomarkers remain major
 obstacle in the road to therapeutic success in these diseases. The present study seeks to
 overcome these roadblocks building on previous work of the Myotonic Dystrophy Clinical
 Research Network (DMCRN) (14-N-0132 study) with the following added features: 1) larger DM1
 cohort including 11 - 70 year old individuals; 2) including DM2 individuals, 3) longer study
 duration; 4) allowing validation of NIH custombuilt devices for longitudinal measurements;
 and 5) including non-muscle endpoints and biomarkers specifically respiratory and central
 nervous system (CNS) function, which are important for survival and quality of life. The goal
 of the current study is to prospectively assess the disease progression over 2 years in
 individuals with DM1 and DM2. Selected tests, imaging and patient-reported outcomes will be
 assessed for ability to quantify disease burden, detect disease progression and predict
 changes. Additionally, we will examine muscle and cerebrospinal fluid (CSF) RNA alternative
 splice events as biomarkers of DM1 and DM2 severity and explore genetic modifiers of DM1 and
 DM2 severity by genome wide association (GWA) study.

 Study population: This study plans to enroll up to 180 participants: 120 individuals with DM1
 and 60 individuals with DM2 (open to both juvenile and adult individuals (11 to 70 years old,
 inclusive)) at the NIH Clinical Center.

 Study Design: This will be a prospective observational study. No treatment will be
 administered as part of this study. Participants will receive standard of care as determined
 by their treating physician. Participants will report to the NIH Clinical Center for 3 visits
 each: at baseline (Visit 1), at 1-year from baseline (Visit 2), and at 2-years from baseline
 (Visit 3). To reduce fatigue and impact on results, each study visit be split into more than
 one trip to the NIH within a 30 day window) and may require the patient to be admitted to the
 clinical center. Each trip to the NIH for a study visit may last up to seven days. Study
 procedures for each visit are outlined in Section 4 and Appendix A. Data and samples will be
 shared with DMCRN investigators participating in Establishing Biomarkers and Clinical
 Endpoints in Myotonic Dystrophy Type 1 (ENDDM1) study as indicated in Appendix B.

 Outcome measures: No specific primary and secondary outcomes will be specified; however, the
 change in the following measures from baseline may be used to characterize the baseline
 status and disease progression over the course of the study: 1) muscle strength; 2) myotonia;
 3) hand and upper arm functional tests; 4) measures of gait, balance and mobility; 5)
 skeletal muscle MRI measures of muscle mass and fatty degeneration; 6) skeletal muscle RNA
 biomarkers from biopsied tissue; 7) cognitive function; 8) brain MRI measures of gray matter
 volume, white matter hyperintensity volume, whole brain volume, integrity of white matter
 tracts measured as mean diffusivity and fractional anisotropy and resting state functional
 connectivity by functional MRI; 9) pulmonary function tests; 10) MRI measures of the
 diaphragm motion and contractility, myocardial function as well as myocardial fat and water
 composition and fibrosis; 11) clinical assessments of sleep, speech and swallow and
 gastrointestinal motility impairment; and 12) CSF RNA biomarkers and genetic modifiers of DM1
 and DM2 severity from a GWA study in collaboration with other DMCRN researchers.
-  INCLUSION CRITERIA:

 -  Age 11 to 70 inclusive

 -  Competent to provide informed consent and assent (consent of a parent or guardian will
 be required for pediatric participants)

 -  Positive genetic test for DM1 or DM2 (Genetic testing for DM1 or DM2 may be determined
 after enrollment

 EXCLUSION CRITERIA:

 -  Concurrent enrollment in a clinical trial or participation in an investigative drug
 trial within 6 months of study entry.

 -  Concurrent pregnancy or planned pregnancy during the course of the study.

 -  Concurrent medical condition that would, in the opinion of the investigator or
 clinical evaluator, compromise performance on study measures:

 -  Clinically significant infections or medical illness within 30 days from study entry.

 -  History of, or abnormal laboratory values indicative of, significant medical,
 neurologic (other than DM1 or DM2), or psychiatric disorders.

 -  A recent history (30 days prior to study entry) of any of the following conditions on
 routine blood screening: white blood cells < 3000, platelets < 100,000, hematocrit <
 30%, symptomatic liver disease with serum albumin < 3 g/L, or creatinine > 1.5 mg%.

 -  Any of the following medical conditions: uncontrolled or insulin-dependent diabetes
 mellitus, congestive heart failure, symptomatic cardiomyopathy, symptomatic coronary
 artery disease, cancer (other than skin cancer) within 5 years from study entry,
 multiple sclerosis, or other serious medical illness.

 -  Other diseases that mimic the signs or symptoms of DM1 or DM2. Coexistence of other
 neuromuscular disease.

 -  Thyroid dysfunction that is untreated (if on thyroid hormone replacement therapy, need
 to have adequate and stable replacement over the previous 6 months from study entry).

 -  Second or third degree heart block, atrial flutter, atrial fibrillation, ventricular
 tachycardia, or is receiving medication for the treatment of cardiac arrhythmia.

 -  Liver or kidney disease requiring ongoing treatment.

 -  Have a seizure disorder.

 -  Drug or alcohol abuse within 3 months of study entry (DSM-V criteria will be used for
 the diagnosis and level of a substance use disorder:

 -  Treatment with supplemental anabolic hormones (including testosterone, human
 recombinant growth hormone, human recombinant insulin like growth factor-1, other
 anabolic drug mixtures) during the previous 12 months from study entry.

 Note: non-ambulatory participants are not excluded but are limited to <15% of enrollment.
 Individuals using a cane or walker will not be examined for gait, balance and mobility.